國家衛生研究院 NHRI:Item 3990099045/7760

NHRI > Institute of Biotechnology and Pharmaceutical Research > Hsing-Pang Hsieh > Periodical Articles > Item 3990099045/7760

Please use this identifier to cite or link to this item: http://ir.nhri.org.tw/handle/3990099045/7760

Title:	CDKN1A-mediated responsiveness of MLL-AF4-positive acute lymphoblastic leukemia to Aurora kinase-A inhibitors
Authors:	Chen, YP;Lin, HJ;Chen, JS;Tsai, MY;Hsieh, HP;Chang, JY;Chen, NF;Chang, KC;Huang, WT;Su, WC;Yang, ST;Chang, WC;Hung, LY;Chen, TY
Contributors:	Institute of Biotechnology and Pharmaceutical Research;National Institute of Cancer Research
Abstract:	Overexpression of Aurora kinases is largely observed in many cancers, including hematologic malignancies. In this study, we investigated the effects and molecular mechanisms of Aurora kinase inhibitors in acute lymphoblastic leukemia (ALL). Western blot analysis showed that both Aurora-A and Aurora-B are overexpressed in ALL cell lines and primary ALL cells. Both VE-465 and VX-680 effectively inhibited Aurora kinase activities in nine ALL cell lines, which exhibited different susceptibilities to the inhibitors. Cells sensitive to Aurora kinase inhibitors underwent apoptosis at an IC50 of ?10–30 nM and displayed a phenotype of Aurora-A inhibition, whereas cells resistant to Aurora kinase inhibitors (with an IC50 more than 10 μM) accumulated polyploidy, which may have resulted from Aurora-B inhibition. Drug susceptibility of ALL cell lines was not correlated with the expression level or activation status of Aurora kinases. Interestingly, RS4;11 and MV4;11 cells, which contain the MLL-AF4 gene, were both sensitive to Aurora kinase-A inhibitors treatment. Complementary DNA (cDNA) microarray analysis suggested that CDKN1A might govern the drug responsiveness of ALL cell lines in a TP53-independent manner. Most importantly, primary ALL cells with MLL-AF4 and CDKN1A expression were sensitive to Aurora kinase inhibitors. Our study suggests CDKN1A could be a potential biomarker in determining the drug responsiveness of Aurora kinase inhibitors in ALL, particularly in MLL-AF4-positive patients.
Date:	2014-08
Relation:	International Journal of Cancer. 2014 Aug;135(3):751-762.
Link to:	http://dx.doi.org/10.1002/ijc.28708
JIF/Ranking 2023:	http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0020-7136&DestApp=IC2JCR
Cited Times(WOS):	https://www.webofscience.com/wos/woscc/full-record/WOS:000335945800022
Cited Times(Scopus):	http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84901058026
Appears in Collections:	[Hsing-Pang Hsieh] Periodical Articles [Jang-Yang Chang] Periodical Articles

Files in This Item:

File	Description	Size	Format
WIL2014020602.pdf		785Kb	Adobe PDF	618	View/Open

Loading...